0001477449-25-000099
SEC filingRevenue decreased 2% due to BetterHelp decline offset by Integrated Care growth; net loss narrowed sharply.
Revenue for Q2 2025 was $631.9M, down 2% YoY from $642.4M, driven by a 9% decline in BetterHelp revenue partially offset by 4% growth in Integrated Care. Cost of revenue increased 1% to $190.5M, while advertising and marketing decreased 2% to $167.5M. Operating loss improved dramatically from $841.1M to $54.4M, primarily due to the absence of a $790M goodwill impairment in the prior year. Net loss narrowed from $837.7M to $32.7M, and EPS improved from -$4.92 to -$0.19. Adjusted EBITDA fell 23% to $69.3M, with margin contracting from 13.9% to 11.0%.
Integrated Care revenue rose 4% to $391.5M, aided by a 2% contribution from acquisitions (Catapult Health and Uplift). U.S. Integrated Care members increased 11% to 102.4M, but average monthly revenue per member declined from $1.36 to $1.27. Segment Adjusted EBITDA margin fell from 17.0% to 14.7% due to higher labor, technology, and device amortization costs. BetterHelp revenue fell 9% to $240.4M as paying users decreased 5% to 0.388M. Despite lower therapist costs and reduced marketing spend, segment Adjusted EBITDA margin dropped from 9.6% to 4.9%.
Management highlighted ongoing uncertainty from tariffs and trade policies, which may impact costs for imported components. The company expects continued positive operating cash flows and noted a new $300M revolving credit facility entered in July 2025. No specific quantitative guidance was provided, but the focus remains on driving Integrated Care membership growth and stabilizing BetterHelp through efficient marketing.
As of June 30, 2025, Teladoc Health held $679.6 million in cash and cash equivalents, a sharp decline from $1.30 billion at December 31, 2024. The decrease was driven primarily by the repayment of $550.6 million in convertible senior notes (the 2025 Notes and Livongo Notes) that matured in May and June 2025. Total assets stood at $2.89 billion, down from $3.52 billion at year-end 2024, largely due to the cash outflow and a $59.1 million goodwill impairment. Total liabilities decreased to $1.47 billion from $2.03 billion, reflecting the debt repayment. Stockholders' equity was $1.42 billion, compared to $1.49 billion at December 31, 2024. The company's current ratio (current assets / current liabilities) improved to 2.67x from 1.77x, as current liabilities fell more sharply than current assets.
The Notes section discloses future minimum lease payments under non-cancelable operating leases totaling $48.0 million as of June 30, 2025. These payments are scheduled as follows: $6.7 million in the remainder of 2025, $11.9 million in 2026, $8.8 million in 2027, $6.8 million in 2028, $5.2 million in 2029, and $8.6 million thereafter. The present value of lease liabilities was $41.9 million. No other purchase commitments (e.g., supply or capacity agreements) were disclosed. The company also has a $1.0 billion principal amount of 1.25% convertible senior notes due 2027 (net carrying value $993.2 million) and a $300.0 million revolving credit facility entered into on July 17, 2025, subsequent to quarter-end.
No share buybacks or dividends were reported. Capital expenditures were $4.0 million for the six months ended June 30, 2025 (0.3% of revenue), plus $57.8 million in capitalized software development costs. The company repaid $550.6 million in convertible notes during the period, leaving only the 2027 Notes outstanding. The new $300.0 million revolving credit facility (entered into July 17, 2025) provides additional liquidity but was undrawn as of the filing date.
The company operates two reportable segments: Integrated Care and BetterHelp. For the three months ended June 30, 2025, Integrated Care generated $391.5 million in revenue (up 3.7% YoY) and BetterHelp generated $240.4 million (down 9.3% YoY). Segment Adjusted EBITDA was $57.5 million for Integrated Care and $11.9 million for BetterHelp, compared to $64.0 million and $25.5 million, respectively, in the prior-year quarter. Geographically, U.S. revenue was $519.7 million (82.2% of total) and international revenue was $112.2 million (17.8%) for Q2 2025.
Teladoc Health reported net cash provided by operating activities of $107.4 million for the six months ended June 30, 2025, an improvement from $97.6 million in the prior-year period, despite a significantly smaller net loss ($125.7 million vs. $919.6 million). The primary driver was the absence of a large goodwill impairment ($59.1 million vs. $790.0 million in H1 2024), combined with non-cash charges like amortization ($173.0 million) and stock-based compensation ($47.5 million).
Capex intensity remained moderate, with capital expenditures of $3.9 million and capitalized software development costs of $57.8 million, totaling $61.8 million. Investing cash flow was heavily negative ($183.0 million) due to $65.3 million for a business combination, $29.6 million for an asset acquisition, and $27.1 million for investments.
Financing activities consumed $549.2 million, driven by $550.6 million in repayment of convertible senior notes. No share repurchases or dividends were reported. The company ended the period with $679.6 million in cash, down from $1.3 billion at the start of the period, reflecting significant outflows. Free cash flow is not explicitly stated but operating cash flow ($107.4M) less capex and capitalized software ($61.8M) would imply approximately $45.6 million.
Notable working capital changes included a $19.3 million increase in accounts payable and a $9.5 million decrease in accrued compensation. Interest paid remained stable at $8.7 million.